ANIK vs JNJ
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
ANIK's Piotroski F-Score of 2/9 indicates weak financial health, with significant red flags in profitability and cash flow. The company reports negative net income and ROE, despite a strong gross margin of 56.56%, suggesting operational inefficiencies. While the debt-to-equity ratio of 0.18 and high current ratio (4.72) point to solid liquidity, the lack of revenue growth (0% YoY) and absence of free cash flow undermine long-term sustainability. The stock trades at a forward P/E of 35.50, which is elevated relative to its lack of earnings growth, and the 63.8% 6-month rally appears speculative rather than fundamentals-driven. Analysts rate it 'strong_buy' with a target of $17.50, but this is not supported by core financial metrics.
JNJ shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
ANIK vs JNJ: Head-to-Head Comparison
This page compares Anika Therapeutics, Inc. (ANIK) and Johnson & Johnson (JNJ) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.